Group 1 - CareDx reported revenue of $86.68 million for the quarter ended June 2025, a year-over-year decline of 6.1% and an EPS of $0.10 compared to $0.25 a year ago [1] - The revenue surprise was -4.45% compared to the Zacks Consensus Estimate of $90.72 million, and the EPS surprise was -16.67% against the consensus estimate of $0.12 [1] - CareDx's shares have returned -33.3% over the past month, while the Zacks S&P 500 composite increased by +0.5% [3] Group 2 - Revenue from Patient and digital solutions was $12.81 million, exceeding the average estimate of $11.91 million, representing a year-over-year change of +19.2% [4] - Revenue from Testing services was $62.03 million, below the average estimate of $67.39 million, indicating a year-over-year decline of -12.5% [4] - Revenue from Product sales was $11.83 million, slightly above the average estimate of $11.69 million, reflecting a year-over-year increase of +11.5% [4]

Core Insights - CareDx reported $86.58 million in revenue for Q4 2024, a 32% year-over-year increase, with an EPS of $0.18 compared to -$0.17 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $85.5 million by 1.26%, and the EPS surpassed the consensus estimate of $0.07 by 157.14% [1] Revenue Breakdown - Revenue from Patient and Digital Solutions was $11.39 million, exceeding the average estimate of $10.99 million by analysts, representing an 18.4% year-over-year increase [4] - Revenue from Testing Services reached $63.82 million, compared to the average estimate of $62.20 million, marking a 36.7% year-over-year increase [4] - Revenue from Products was $11.37 million, surpassing the average estimate of $10.83 million, reflecting a 23% year-over-year increase [4] Stock Performance - CareDx shares have returned -8.5% over the past month, while the Zacks S&P 500 composite has changed by -2.3% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]